Hikma Pharmaceuticals

Strong Generics-led finish to 2023

22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."

PDF page sample
Pages
55
Language
English
Published on
22/02/24
Download
You may also be interested by these reports :
24/09/26
A years/decades long search for revolutionary multi-blockbuster drug(s), a phenomenal run for some years and then concerns sprout around ...
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...
21/09/26
Siegfried’s (Buy, Switzerland) post-Covid success story has been nipped in the bud by three years of low-single-digit (LSD) growth (in CHF). ...
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO